Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 1, 2008, Pages 1-5

  Miao, Li Yan ^a   Huang, Chen Rong ^a   Hou, Jian Quan ^a   Qian, Mei Ying ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

ABCB1; CYP3A5; Gene polymorphism; Renal transplant recipients; Sirolimus

Indexed keywords

ADENINE; CYCLOSPORIN; CYTOCHROME P450 3A5; GUANINE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMINE;

ADULT; ARTICLE; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GRAFT RECIPIENT; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; VOLUNTEER;

ADULT; ANALYSIS OF VARIANCE; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; SIROLIMUS; TACROLIMUS;

EID: 39449086203     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.577     Document Type: Article

References (16)

1. Stepkowski SM. Sirolimus, a potent new immunosuppressive drug for organ transplantation. Ann Transplant 1996; 1(3): 19-25.
2. Stallone G, Infante B, Gesualdo L. Immunosuppressive drugs and renal transplantation. G Ital Nefrol 2005; 22(Suppl. 33): S76-S79.
3. Brattstrom C, Wilczek H, Tyden G, Bottiqer Y, Sawe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65: 1272-1274.
4. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leucopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000; 69: 2085-2090.
5. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (ABCB1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248-260.
6. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 1998; 285: 1104-1112.
7. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
8. Hustert E, Haber M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779.
9. Crowe A, Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 1998; 15: 1666-1672.
10. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human ABCB1(P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13-33.
11. Le Meur Y, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006; 80: 51-60.
12. Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and ABCB1 polymorphisms and steroids. Transplantation 2005; 80: 977-984.
13. Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005; 5: 595-603.
14. Ren B, Shu X, Deng B, Wang CX, Hong XD. Determination of sirolimus in human whole blood by HPLC. Clin Pharm J 2004; 39: 52-53.
15. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22(Suppl. B): B101-B121.
16. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97-109.